iMS

General

Cell Line

hPSCreg Name
MLi004-A
Alternative name(s)
iMS
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
AIBNi015-A
(SPG1-AU01C15)
Donor diseases:
hereditary spastic paraplegia 56
WTSIi620-A
(HPSI0616i-uegn_3)
Donor diseases:
Spastic paraplegia
UKBi014-A
(A-257s2)
Donor diseases:
Walker-Warburg syndrome
WTSIi624-A
(HPSI0616i-uofs_5)
Donor diseases:
Spastic paraplegia
WTSIi648-A
(HPSI0616i-mesv_4)
Donor diseases:
Spastic paraplegia
WTSIi665-A
(HPSI0616i-euia_7)
Donor diseases:
Spastic paraplegia
WTSIi479-B
(HPSI0616i-beyk_2)
Donor diseases:
Spastic paraplegia
WTSIi620-B
(HPSI0616i-uegn_1)
Donor diseases:
Spastic paraplegia
WTSIi648-B
(HPSI0616i-mesv_5)
Donor diseases:
Spastic paraplegia
WTSIi686-B
(HPSI0616i-baxr_6)
Donor diseases:
Spastic paraplegia
WTSIi624-B
(HPSI0616i-uofs_2)
Donor diseases:
Spastic paraplegia
WTSIi498-B
(HPSI0616i-biln_1)
Donor diseases:
Spastic paraplegia
WTSIi686-A
(HPSI0616i-baxr_5)
Donor diseases:
Spastic paraplegia
WTSIi703-B
(HPSI0816i-hizl_4)
Donor diseases:
Spastic paraplegia
WTSIi703-A
(HPSI0816i-hizl_3)
Donor diseases:
Spastic paraplegia
WTSIi479-A
(HPSI0616i-beyk_6)
Donor diseases:
Spastic paraplegia
WTSIi498-A
(HPSI0616i-biln_2)
Donor diseases:
Spastic paraplegia
WTSIi485-B
(HPSI0614i-kecw_4)
Donor diseases:
Bardet-Biedl syndrome
WTSIi399-B
(HPSI0614i-gawh_12)
Donor diseases:
Bardet-Biedl syndrome
WTSIi415-B
(HPSI0614i-laig_2)
Donor diseases:
Bardet-Biedl syndrome
ZZUi017-A
(ZZU-iPS-SCA6-001)
Donor diseases:
Spinocerebellar Ataxia Type 6
WTSIi033-A
(HPSI1013i-aetc_1)
Donor diseases:
Bardet-Biedl syndrome
WTSIi034-A
(HPSI0913i-kojv_2)
Donor diseases:
Bardet-Biedl syndrome
WTSIi035-A
(HPSI0913i-gooj_1)
Donor diseases:
Bardet-Biedl syndrome
WTSIi457-B
(HPSI0115i-iinu_5)
Donor diseases:
Bardet-Biedl syndrome
WTSIi527-B
(HPSI0216i-heub_6)
Donor diseases:
Usher syndrome
WTSIi474-B
(HPSI0216i-dewh_4)
Donor diseases:
Usher syndrome
WTSIi510-B
(HPSI0216i-xanu_6)
Donor diseases:
Usher syndrome
WTSIi548-B
(HPSI0416i-mefc_1)
Donor diseases:
Usher syndrome
WTSIi399-A
(HPSI0614i-gawh_7)
Donor diseases:
Bardet-Biedl syndrome
WTSIi488-B
(HPSI0516i-oazw_3)
Donor diseases:
Usher syndrome
WTSIi464-B
(HPSI0516i-eitu_4)
Donor diseases:
Usher syndrome
WTSIi486-B
(HPSI0516i-hapz_2)
Donor diseases:
Usher syndrome
WTSIi669-A
(HPSI0816i-aorf_1)
Donor diseases:
Usher syndrome
WTSIi415-A
(HPSI0614i-laig_1)
Donor diseases:
Bardet-Biedl syndrome
WTSIi149-A
(HPSI0913i-laia_4)
Donor diseases:
Bardet-Biedl syndrome
WTSIi150-A
(HPSI0414i-jetz_1)
Donor diseases:
Bardet-Biedl syndrome
WTSIi419-A
(HPSI0514i-kidt_1)
Donor diseases:
Bardet-Biedl syndrome
WTSIi153-A
(HPSI0414i-puvg_1)
Donor diseases:
Bardet-Biedl syndrome
WTSIi422-A
(HPSI0414i-zazi_4)
Donor diseases:
Bardet-Biedl syndrome
WTSIi155-A
(HPSI0414i-hutq_1)
Donor diseases:
Bardet-Biedl syndrome
WTSIi156-A
(HPSI0414i-xugr_2)
Donor diseases:
Bardet-Biedl syndrome
WTSIi157-A
(HPSI0614i-eavo_1)
Donor diseases:
Bardet-Biedl syndrome
TRDSi004-A
(TRDS-Cardio-012)
Donor diseases:
long QT syndrome 2
WTSIi426-A
(HPSI0714i-mejk_1)
Donor diseases:
Bardet-Biedl syndrome
WTSIi160-A
(HPSI0914i-verf_1)
Donor diseases:
Bardet-Biedl syndrome
Last update 19th July 2021
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Faculty of Medicine University of Ljubljana (ML)
Owner Faculty of Medicine University of Ljubljana (ML)

External Databases

BioSamples SAMEA8868434
Cellosaurus CVCL_A8HI
CLO CLO_0103314
Wikidata Q107116382

General Information

Publications
* Is the cell line readily obtainable for third parties?
No

Donor Information

General Donor Information

Sex female
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Epidermolysis Bullosa Dystrophica, Autosomal Recessive
The donor is a carrier of a disease-associated mutation and affected.
Stage
Deceased
Synonyms
  • Recessive Dystrophic Epidermolysis Bullosa
  • RDEB
  • Epidermolysis Bullosa Dystrophica, Autosomal Recessive
Genetic variants
Is the medical history available upon request? No
Is clinical information available? No

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
46XX
Karyotyping method: Array CGH

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA8868436

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Contact information / weblink Professor John McGrath/Dr Joey Lai-Cheong/Dr Suzanne Clements Genetic Skin Disease Group St John’s Institute of Dermatology 9th Floor Guy’s Tower Guy’s Hospital London, SE1 9RT Tel: +44 (0)20 71886353 E-mails: john.mcgrath@kcl.ac.uk; joey.lai-cheong@kcl.ac.uk; suzanne.clements@kcl.ac.uk
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? No
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? No
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? Yes
Details on restriction to research project Characterisation of molecular and structural skin abnormalities in inherited skin disorders, Prof Dr John McGrath
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? Yes
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? Yes
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? Yes
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Does consent permit access to medical records of the donor? No
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? St Thomas Ethics Committee, South London REC office 3
Approval number 07/H0802/104
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Thermo Fisher Scientific
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell type
Fibroblast
Synonyms
  • fibroblast
  • Fibroblasts
  • Fibroblast
  • FIBROBLAST
show more synonyms
Source cell origin
skin fibroblast
Passage number reprogrammed p5

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
No
Methods used
RT-PCR
Notes on reprogramming vector detection At p13 sendai virus not detected any longer
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Type of used vector free reprogramming factor(s)
mRNA
mRNA

Other

Selection criteria for clones Morphology
Derived under xeno-free conditions
Yes
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
O2 Concentration 5 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: NutriStem hPSC XF Medium
Main protein source:
Serum concentration: %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
NANOG
Yes
TRA 1-60
Yes
TRA 1-81
Yes
OCT4
Yes
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
Alpha fetoprotein
Yes
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
Smooth muscle actin
Yes
Morphology
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
Tubulin beta 3
Unknown
Morphology

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46XX
Passage number: P13
Karyotyping method: Array CGH

Other Genotyping (Cell Line)